Kenneth Shank, DO
Family Medicine · Albemarle, NCNPI 1083695159
Payments from drug & device makers
Across 457 payments — averaging $16.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$1K
- Pfizer$672
- AbbVie$587
- Boehringer Ingelheim$507
- Lilly USA, LLC$484
- plus $3K from 33 others
What the payments were for
- Food & beverage$7,71399%
- Education$411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 51 | $1,093 |
| Novo Nordisk | 94 | $1,084 |
| Pfizer | 42 | $672 |
| AbbVie(2 entities) | 38 | $587 |
| Boehringer Ingelheim | 29 | $507 |
| Lilly USA, LLC | 33 | $484 |
| Amgen(2 entities) | 25 | $399 |
| Exact Sciences | 18 | $393 |
| Bayer | 13 | $300 |
| Novartis | 17 | $286 |
| Sanofi-aventis U.S. LLC | 12 | $273 |
| Abiomed | 3 | $161 |
| Johnson & Johnson | 9 | $160 |
| E.r. Squibb & Sons, L.L.C. | 9 | $145 |
| Xeris Pharmaceuticals, Inc. | 7 | $139 |
| Teva Pharmaceuticals USA, Inc. | 7 | $136 |
| Eisai Inc. | 5 | $132 |
| Shield Therapeutics Inc | 6 | $103 |
| Otsuka America Pharmaceutical, Inc. | 5 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $74 |
| Amarin Pharma, Inc. | 3 | $54 |
| Forte Bio-pharma LLC | 2 | $45 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $42 |
| Abbott | 2 | $41 |
| GSK | 2 | $40 |
| Esperion Therapeutics, Inc. | 2 | $32 |
| Ironwood Pharmaceuticals, Inc | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 2 | $29 |
| Biohaven Pharmaceuticals, Inc. | 1 | $28 |
| Merck | 2 | $26 |
| Mylan Specialty L.p. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $22 |
| Seqirus USA Inc | 1 | $20 |
| Idorsia Pharmaceuticals US Inc | 1 | $19 |
| Boston Scientific | 1 | $19 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Almatica Pharma LLC | 1 | $17 |
| Nevro Corp. | 1 | $16 |
| Daiichi Sankyo Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,754 in reported general payments places this provider in the 90th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 317 | $287,666 |
| TrulicityDulaglutide | 145 | $170,710 |
| MounjaroTirzepatide | 142 | $169,980 |
| JardianceEmpagliflozin | 125 | $139,872 |
| OzempicSemaglutide | 94 | $103,104 |
| FarxigaDapagliflozin Propanediol | 97 | $102,646 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 71 | $66,720 |
| XareltoRivaroxaban | 48 | $54,994 |
| Tresiba Flextouch U-100Insulin Degludec | 55 | $38,309 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 41 | $36,519 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 25 | $31,732 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $29,873 |
| NucyntaTapentadol Hcl | 22 | $26,529 |
| LinzessLinaclotide | 26 | $25,826 |
| Repatha SureclickEvolocumab | 30 | $25,275 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $484 | $340,690287 claims |
| PfizerEliquis, Abrysvo | $672 | $296,125346 claims |
| Boehringer IngelheimJardiance, Tradjenta | $507 | $163,056146 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $1,093 | $150,039166 claims |
| Novo NordiskOzempic, Rybelsus | $1,084 | $122,690108 claims |
| Johnson & JohnsonXarelto | $160 | $54,99448 claims |
| AbbVieLinzess, Vraylar, Synthroid | $587 | $51,041143 claims |
| GSKTrelegy Ellipta, Shingrix | $40 | $24,15463 claims |
| MerckJanumet | $26 | $9,56213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Albemarle
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
- Stephen JonesShelby$4.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.